1. Please use the following CASE to answer questions 1 and 3:
JP is a 78-year-old male with newly diagnosed Rai Stage 4, immunoglobulin heavy chain (IGHV) unmutated chronic lymphocytic leukemia (CLL). His past medical history includes uncontrolled atrial fibrillation, hypertension, and type 2 diabetes mellitus. His home medication list is as follows: metoprolol, lisinopril, metformin, and apixaban.

Which of the following therapies is the most appropriate for first-line treatment of his CLL?

2. You decide to treat JP with venetoclax + obinutuzumab. His PET scan demonstrates some lymphadenopathy, with the largest lymph node measuring 4 cm. His most recent laboratory values indicate an absolute lymphocyte count of 20,000 x 109/L, serum creatinine of 0.8 mg/dL, uric acid of 6 mg/dL, potassium of 4.2 mmol/L, phosphorous of 3.8 mg/dL, and calcium of 10 mg/dL. Which of the following is the best strategy to prevent tumor lysis syndrome in JP?

3. Which of the following is approved by the United States Food and Drug Administration (FDA) and is recommended by the National Comprehensive Cancer Network (NCCN) guidelines as a treatment for relapsed/refractory (R/R) follicular lymphoma (FL)?

4. You are providing an in-service on new drug approvals in lymphoma to your infusion nursing staff. Which of the following pieces of information will you include in this presentation?

5. You are counseling a patient on idelalisib for their relapsed/refractory follicular lymphoma. Which of the following conditions is listed in a black box warning associated with idelalisib and should be included in your patient education?

Evaluation Questions

6. How confident are in your treatment choices for JP?

« Return to Activity